Despite their superior efficacy over tamoxifen for hormone-sensitive breast cancer31, aromatase inhibitors may increase the risk of cardiovascular diseases, including hypertension, dyslipidemia, and ischemic heart disease32,33. Here, CYP19A1 is linked to cardiovascular disorder.